Apatinib combined with chemotherapy or concurrent chemoradiotherapy in patients with recurrent or advanced cervical cancer: a phase II, randomized controlled trial

A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024143

Enrollment

Unknown

Registered

2019-06-27

Start date

2016-07-01

Completion date

Unknown

Last updated

2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

Experimental group:apatinib+chemoradiotherapy

Control group:chemoradiotherapy

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients had been histological diagnosed with cervical cancer; Aged>18 years; At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, ECOG score<3; No serious heart, liver or kidney insufficiency; Patients with recurrent cervical cancer and those with advanced disease in stage IVB.

Exclusion criteria

Exclusion criteria: Patients allergic to apatinib; Patients with active hemorrhage; Patients with intestinal perforation or bowel ileus; Patients within 30 days after a major surgery; Hypertensive patients with uncontrolled blood pressure through drug-therapy.

Design outcomes

Primary

Measure	Time frame
progression-free survival (PFS);	—

Secondary

Measure	Time frame
objective response rate (ORR);disease control rate (DCR);overall survival (OS);	—

Countries

China

Contacts

Public ContactLi Sun

Shandong Academy of Medical Sciences

sunli766@163.com+86 18953109686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026